Abstract
P53 is one of the most important tumour suppressor proteins. While its activity seems to be dispensable for normal proliferating cells, this protein is required to maintain genomic integrity after DNA damage. In response to cellular stress, the amount of p53 protein accumulates and fulfils its function as a transcription factor. Most of the genes that are regulated by p53 control progression through the cell cycle or initiate cell death. A large number of proteins have been identified in recent years that control the activity of this important tumour suppressor protein. These proteins regulate the turnover of p53, its association with co-repressor and co-activator proteins and target gene promoters or impinge on p53 oligomerisation. This review shall give an overview of our current knowledge on how the activity of the p53 protein is controlled.
Keywords: p53, DNA damage, phosphorylation, acetylation, ubiquitination, protein-protein interactions
Current Chemical Biology
Title: Regulation of p53 Activity
Volume: 4 Issue: 1
Author(s): Karen A. Boehme and Christine Blattner
Affiliation:
Keywords: p53, DNA damage, phosphorylation, acetylation, ubiquitination, protein-protein interactions
Abstract: P53 is one of the most important tumour suppressor proteins. While its activity seems to be dispensable for normal proliferating cells, this protein is required to maintain genomic integrity after DNA damage. In response to cellular stress, the amount of p53 protein accumulates and fulfils its function as a transcription factor. Most of the genes that are regulated by p53 control progression through the cell cycle or initiate cell death. A large number of proteins have been identified in recent years that control the activity of this important tumour suppressor protein. These proteins regulate the turnover of p53, its association with co-repressor and co-activator proteins and target gene promoters or impinge on p53 oligomerisation. This review shall give an overview of our current knowledge on how the activity of the p53 protein is controlled.
Export Options
About this article
Cite this article as:
Boehme A. Karen and Blattner Christine, Regulation of p53 Activity, Current Chemical Biology 2010; 4 (1) . https://dx.doi.org/10.2174/2212796811004010001
DOI https://dx.doi.org/10.2174/2212796811004010001 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics Mechanisms of Colon Cancer Prevention with and Beyond COX-2 Inhibition
Current Topics in Medicinal Chemistry Polyphenols and Aging
Current Aging Science Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Current Topics in Medicinal Chemistry Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets